The growing push to expand access to peptide-based therapies is raising complex regulatory and market questions, particularly as policymakers consider reclassifying certain compounds currently restricted by the FDA. As highlighted in PharmaVoice, increased demand for peptides, driven by interest in weight loss and longevity, has fueled both legitimate and gray market activity, with consumers seeking alternatives to high-cost or limited-access treatments. While potential policy changes could bring peptides back into regulated channels through compounding pharmacies, they also introduce new risks related to safety, oversight, and market dynamics.
Frier Levitt partner Edgar Asebey underscores the legal and practical challenges surrounding these developments. He notes the unusual nature of major policy discussions occurring outside traditional regulatory channels.
“For a gray-haired regulatory attorney, it was interesting to find out such huge potential policy changes on a podcast as opposed to the Federal Register or from the FDA.”
Asebey also cautions that many peptides lack sufficient clinical data and regulatory approval, emphasizing these compounds are not pharmaceutical grade. He further highlights the economic realities driving the market, explaining that limited incentives for formal drug development, and ongoing consumer demand, will likely sustain both regulated and unregulated channels, even if reclassification occurs.
Read the full article in PharmaVoice.
